Keywords: ap, pharma, apf530, ready, submission, california, usa-based
AP Pharma's APF530 ready for submission
Article | 06 October 2008
California, USA-based specialty pharmaceutical company AP Pharma has reported positive results from a pivotal Phase III study comparing APF530 (sustained-release ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
